Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

Abstract

Background: The long-term safety and efficacy of fremanezumab were evaluated in a 52-week extension study (NCT02638103). Patient satisfaction with fremanezumab, dosing preferences, and patient-reported outcomes were assessed in a subpopulation who completed the extension study and consented to a follow-up questionnaire. Methods: In the extension study (N = 1842), adults with migraine were randomized to quarterly or monthly fremanezumab. After completing active treatment, patients answered a survey evaluating patient satisfaction, treatment and dosing preferences, and changes in patient-reported outcomes. Results: Of the 557 patients who could have been contacted upon completing the extension study, 302 consented and 253 completed the survey. The mean (standard deviation) satisfaction rating for fremanezumab was 6.1 (1.4; 1 = "extremely dissatisfied" to 7 = "extremely satisfied"). Most patients (175 [69.2%]) preferred quarterly over monthly fremanezumab dosing. Among patients taking antiepileptics (most common class of prior preventive medication; n = 130), 91.5% preferred fremanezumab. Patients reported improvements in anxiety (74 [67.9%]), sleep quality (143 [56.5%]), and quality of time spent with others (210 [83.0%]) with fremanezumab. Conclusion: In this study, treatment satisfaction with fremanezumab was high, most patients preferred quarterly fremanezumab dosing, and fremanezumab was generally preferred to prior preventive medications.

PEARL Study Protocol: a Real-World Study of Fremanezumab Effectiveness in Patients with Chronic or Episodic Migraine

“…In a long-term extension study following the pivotal 3-month studies of fremanezumab in CM and EM, efficacy was maintained for a further 12 months of treatment, with no evidence of wearing off at the end of the quarterly or monthly dose intervals [18,24]. Additionally, patients reported high levels of treatment satisfaction, as well as improvements in sleep quality, reduced anxiety and increased quality of time spent with others [25]. However, real-world effectiveness, treatment persistence and adherence data are limited for fremanezumab and other CGRP pathway-targeting mAbs for the prevention of CM or EM.…”

Current status of calcitonin gene-related peptide-based therapies in migraine: a scoping review

“…51 Though no difference was seen in the efficacy of quarterly and monthly doses, results from the HALO study (NCT02638103) showed that 69% patients preferred quarterly fremanezumab. 52,53 In addition to reaching the migraine related efficacy end-points, patients also reported improvement in quality of time spent with others, anxiety and sleep quality. 53 The most commonly reported TEAEs were injection site reactions like induration, pain and erythema.…”

“…52,53 In addition to reaching the migraine related efficacy end-points, patients also reported improvement in quality of time spent with others, anxiety and sleep quality. 53 The most commonly reported TEAEs were injection site reactions like induration, pain and erythema. 51,52 EPTINEZUMAB Eptinezumab (VYEPTI TM ) was approved by the US-FDA in February 2020 for the prevention of migraine in adults.…”

Tratamiento preventivo de la migraña con fremanezumab subcutáneo

“…Actualmente se han publicado un metaanálisis (n = 3.404) 41 y un pool data-análisis (n = 2.566) 42 que han concluido que la seguridad y pacientes con fremanezumab presentan mayor número de días sin nada de dolor y estado funcional normal que los pacientes tratados con placebo (n = 563) 53 . Además, se ha observado una mejoría significativa en la calidad del sueño, la ansiedad y la calidad del tiempo pasado con allegados (n = 253) 54 .…”